Adverse events associated with pediatric complementary and alternative medicine in the Netherlands: a national

Björn Vos1, Jan Peter Rake2,3,4, Arine Vlieger5

  • 1Martini Hospital, Groningen, Netherlands. vos@mzh.nl.

Insights

Adverse events from pediatric complementary and alternative medicine (CAM) are rare in the Netherlands. Most risks stem from delaying conventional treatment rather than direct CAM toxicity, especially in infants.

Area of Science:

  • Pediatric Medicine
  • Complementary and Alternative Medicine (CAM)
  • Public Health Surveillance

Background:

  • Pediatric use of complementary and alternative medicine (CAM) is prevalent in the Netherlands.
  • The potential risks associated with pediatric CAM use remain largely uncharacterized.
  • Previous international studies indicated that severe adverse events can occur with pediatric CAM usage.

Purpose of the Study:

  • To investigate the prevalence and nature of adverse events linked to pediatric CAM usage in the Netherlands.
  • To identify the direct and indirect risks associated with CAM therapies in children.
  • To inform parents, pediatricians, and CAM providers about potential pediatric CAM-related adverse events.

Main Methods:

  • A 3-year survey conducted by the Dutch Pediatric Surveillance Unit.
  • Pediatricians were tasked with registering adverse events associated with pediatric CAM usage.
  • Analysis of registered cases to categorize event types and associated therapies.

Main Results:

  • A total of 32 unique adverse events were registered over 3 years.
  • Twenty-two events were indirect, resulting from treatment delays, dietary issues, or misdiagnoses by CAM providers.
  • Nine direct adverse events (bodily harm, toxicity) were reported, with one-third affecting infants; supplements, manual therapies, and herbs were implicated.

Conclusions:

  • Adverse events associated with pediatric CAM use in the Netherlands are relatively infrequent.
  • The majority of adverse events are indirect, primarily due to the interruption or delay of conventional medical treatment.
  • Vigilance for both direct and indirect adverse events is crucial for all stakeholders, particularly for infants using CAM.